D
iabetes is associated with an increased risk of various forms of cancer, such as cancer of the liver, colon, pancreas, breast, bladder, and kidney. Metformin, widely given to patients with type 2 diabetes, works by inhibiting hepatic glucose production through an LKB1 (serine-threonine liver kinase B1)/AMP-activated protein kinase (AMPK)-mediated mechanism. LKB1 is a wellrecognized tumor suppressor. Activation of AMPK by LKB1 plays an important role in inhibiting cell growth. It has been suggested that metformin use in patients with diabetes may reduce their risk of cancer (1) . Some studies have reported that diabetic patients taking metformin showed decreased cancer risk (2, 3) . However, several studies have shown that metformin does not reduce the risk of cancer in patients with diabetes (4, 5) . Little information is available on the subject considering non-Caucasian ethnicity. We used representative National Health Insurance datasets for Taiwan to form a cohort to assess the total number of cancer incidences in relation to metformin use among diabetic patients.
This study used a sub-dataset composed of 1 million randomly selected patients from all enrollees registered. We used the ICD-9, Clinical Modification (ICD-9-CM), to identify newly diagnosed diabetic patients and patients who had undergone treatment during the period 1998-2009 (ICD-9-CM 250; n 5 37,055). We then excluded patients with a history of cancer (ICD-9-CM 140-208) before the diabetes index date. The patients who were diagnosed with malignant cancer (ICD-9-CM 140-208) during the test period were identified as the cancer case group (n 5 2,158). The patients without a cancer diagnosis before 31 December 2010, matched by age, sex, and study period, were designated as the noncancer group (n 5 8,609). We then analyzed the effects of metformin use on cancer risk by using a multivariable logistic regression model. All analyses were performed using SAS statistical software (version 9.1 for Windows).
The results showed that there was no significant relationship between metformin use and cancer incidence (odds ratio Acknowledgments-This work was supported by the study projects (DMR-100-076 and DMR-100-077) in our hospital, Taiwan S.-Y.W. and C.-S.C. participated in the study conception and design and data analysis and interpretation, wrote the manuscript, and gave final approval of the manuscript. C.-H.M. participated in the study conception and design, collected and assembled data, participated in data analysis and interpretation, wrote the manuscript, and gave final approval of the manuscript. S.-T.T. provided O N L I N Estudy materials, wrote the manuscript, and gave final approval of the manuscript. M.-C.L. participated in the study conception and design and data analysis and interpretation, wrote the manuscript, and gave final approval of the manuscript. F.-C.S. provided study materials, wrote the manuscript, and gave final approval of the study. C.-H.K. participated in the study conception and design and data analysis and interpretation, wrote the manuscript, and gave final approval of the manuscript. C.-H.K. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. 
